Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPIX NASDAQ:JMAC OTCMKTS:OTLC NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPIXESSA Pharma$1.88+0.5%$1.73$1.40▼$7.88$83.01M1.56443,070 shs185,577 shsJMACMaxpro Capital Acquisition$6.15+3.0%$6.28$7.50▼$19.22$82.58M0.0174,040 shs101,532 shsOTLCOncotelic Therapeutics$0.05+0.4%$0.05$0.02▼$0.07$20.74M-0.75133,815 shs108,459 shsQNCXQuince Therapeutics$1.85-0.5%$1.42$0.51▼$2.45$84.57M0.96232,259 shs108,012 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPIXESSA Pharma0.00%0.00%+8.09%+5.65%-63.41%JMACMaxpro Capital Acquisition-8.15%-0.67%+4.83%-3.94%+2,812.20%OTLCOncotelic Therapeutics-0.39%-0.59%+13.65%-12.41%+80.78%QNCXQuince Therapeutics0.00%+1.64%+28.28%+51.22%+144.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPIXESSA Pharma0.9524 of 5 stars1.02.00.00.02.22.51.3JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AQNCXQuince Therapeutics3.097 of 5 stars3.64.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPIXESSA Pharma 2.00Hold$2.006.38% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AOTLCOncotelic Therapeutics 0.00N/AN/AN/AQNCXQuince Therapeutics 3.29Buy$8.00332.43% UpsideCurrent Analyst Ratings BreakdownLatest OTLC, JMAC, QNCX, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/13/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/4/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AOTLCOncotelic Therapeutics$70K297.47$0.01 per share9.89$0.02 per share2.55QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AOTLCOncotelic Therapeutics-$4.52M-$0.01N/A∞N/AN/A-14.16%-4.41%N/AQNCXQuince Therapeutics-$56.83M-$1.39N/AN/AN/AN/A-117.52%-34.22%8/12/2025 (Estimated)Latest OTLC, JMAC, QNCX, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025QNCXQuince Therapeutics-$0.28N/AN/AN/AN/AN/A8/4/2025Q3 2025EPIXESSA Pharma-$0.2430N/AN/AN/AN/AN/A5/13/2025Q1 2025QNCXQuince Therapeutics-$0.24-$0.34-$0.10-$0.34N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPIXESSA PharmaN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPIXESSA PharmaN/A67.1567.15JMACMaxpro Capital AcquisitionN/AN/AN/AOTLCOncotelic TherapeuticsN/A0.010.01QNCXQuince Therapeutics0.824.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPIXESSA Pharma75.12%JMACMaxpro Capital Acquisition73.18%OTLCOncotelic TherapeuticsN/AQNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipEPIXESSA Pharma15.50%JMACMaxpro Capital Acquisition19.27%OTLCOncotelic Therapeutics39.22%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableOTLCOncotelic Therapeutics20408.29 million248.16 millionNot OptionableQNCXQuince Therapeutics6045.47 million36.24 millionOptionableOTLC, JMAC, QNCX, and EPIX HeadlinesRecent News About These CompaniesBrokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) PT at $8.00July 24 at 4:55 AM | americanbankingnews.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by AnalystsJuly 21, 2025 | marketbeat.comBrookline Capital Management Comments on QNCX Q3 EarningsJuly 21, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral CapitalJuly 17, 2025 | marketbeat.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...July 12, 2025 | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesJune 26, 2025 | marketbeat.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18, 2025 | businesswire.comQuince Therapeutics raises $11.5 million in private placementJune 14, 2025 | investing.comQuince Therapeutics Raises $11.5M in Private PlacementJune 13, 2025 | tipranks.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12, 2025 | businesswire.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comQuince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026May 15, 2025 | seekingalpha.comQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finance.yahoo.comQuince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.comQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsMarch 24, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLC, JMAC, QNCX, and EPIX Company DescriptionsESSA Pharma NASDAQ:EPIX$1.88 +0.01 (+0.27%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Maxpro Capital Acquisition NASDAQ:JMAC$6.15 +0.18 (+3.02%) As of 07/24/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Oncotelic Therapeutics OTCMKTS:OTLC$0.05 +0.00 (+0.39%) As of 03:28 PM EasternOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.Quince Therapeutics NASDAQ:QNCX$1.85 -0.01 (-0.54%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.03 (+1.89%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
